Therefore, we conducted this meta‐analysis to determine whether first‐line PD‐(L)1 inhibitor plus chemotherapy (immunochemotherapy) was superior to chemotherapy in the first‐line treatment of ES‐SCLC. The gene discussed is CD274; the disease is small cell lung carcinoma.